Drospirenone and estradiol: a new option for the postmenopausal woman

Climacteric. 2007 Feb:10 Suppl 1:3-10. doi: 10.1080/13697130601114859.


The efficacy of estrogen with or without a progestogen as hormone replacement therapy (HRT) for menopausal symptoms is well-established. Recent large-scale randomized studies with combined estrogen/progestogen therapy (EPT) have raised a number of safety issues, specifically the potential risk for coronary heart disease. Subsequent analyses and other studies have indicated that HRT may be cardioprotective in younger postmenopausal women. A new continuous EPT combines natural 17beta-estradiol (E2) 1 mg with the novel progestin, drospirenone (DRSP) either 0.5 or 2 mg. DRSP has a physiological profile closer to that of natural progesterone than any other synthetic progestin. This paper reviews recent clinical trial data demonstrating the efficacy and safety of combined DRSP/E2 therapy as EPT in postmenopausal women. DRSP/E2 provides symptomatic relief of vasomotor symptoms and improvement in genitourinary atrophy. DRSP/E2 protects against endometrial hyperplasia and reduces the risk of osteoporosis. Combined DRSP/E2 therapy has a favorable impact on cholesterol and triglyceride levels, and decreases blood pressure in women with elevated blood pressure. The favorable efficacy and safety profile of DRSP/E2, and potential for long-term health benefits, represents a new option for the effective management of menopause and its clinical sequelae.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Androstenes / administration & dosage*
  • Androstenes / adverse effects
  • Drug Combinations
  • Estradiol / administration & dosage*
  • Estradiol / adverse effects
  • Estrogen Replacement Therapy* / adverse effects
  • Female
  • Health Status
  • Humans
  • Osteoporosis, Postmenopausal / prevention & control
  • Postmenopause / drug effects*
  • Quality of Life


  • Androstenes
  • Drug Combinations
  • estradiol-drospirenone combination
  • Estradiol